Impact of Individual Cognitive Remediation for Parkinson's Disease
Status: | Recruiting |
---|---|
Conditions: | Cognitive Studies, Cognitive Studies, Parkinsons Disease |
Therapuetic Areas: | Neurology, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 40 - 75 |
Updated: | 8/11/2018 |
Start Date: | July 12, 2018 |
End Date: | November 2018 |
Contact: | Anu Raj, Psy. D |
Email: | Anu.Raj@nyit.edu |
Phone: | 516-686-4909 |
This is an interventional clinical trial that will be conducted as a pilot project.
Investigators hope to conduct the study to obtain at least 10 study completers.
The plan is to screen 20 Parkinson's Disease (PD) patients attending the Academic Health Care
Center (AHCC) at NYIT College of Osteopathic Medicine clinic and enroll the eligible
candidates based on the inclusion and exclusion criteria. Subjects will have 11 study visits
over the 11-week period. Subjects cognition will be assessed using a paper-based Test of
Memory and Learning (TOMAL) tool. The same tool will be used to asses and compare the
cognition at baseline, and end study visits. The weekly 30-mins of cognitive remediation
exercises will be done using the Brain. HQ cognitive remediation software.
Investigators hope to conduct the study to obtain at least 10 study completers.
The plan is to screen 20 Parkinson's Disease (PD) patients attending the Academic Health Care
Center (AHCC) at NYIT College of Osteopathic Medicine clinic and enroll the eligible
candidates based on the inclusion and exclusion criteria. Subjects will have 11 study visits
over the 11-week period. Subjects cognition will be assessed using a paper-based Test of
Memory and Learning (TOMAL) tool. The same tool will be used to asses and compare the
cognition at baseline, and end study visits. The weekly 30-mins of cognitive remediation
exercises will be done using the Brain. HQ cognitive remediation software.
Inclusion Criteria:
1. Subjects must be between 40 and 75 years old (including both ages) at the time of
study screening.
2. Subjects must have a diagnosis of Parkinson's Disease by a physician.
3. Subjects must demonstrate adequate decisional capacity, in the judgment of the
consenting study staff member, to make a choice about participating in this research
study.
4. Subjects must have been clinically stable (non-acute) for 2 weeks prior to consent; in
the judgment of the Investigator.
5. Subjects with a cognition level between Impaired and Average (scaled score between
4-12 or Index Score between 70-110) based on TOMAL Cognitive assessment at Visit 1
6. Subjects must have the visual, auditory, and motor capacity to use the intervention in
the judgment of the Principal Investigator.
Exclusion Criteria:
1. Subjects who are participating in a concurrent research study or another
interventional clinical trial 30 days prior to consenting.
2. Subjects having a history of mental retardation or pervasive developmental disorder;
or other co-morbid neurological disorder (e.g., epilepsy.)
3. Subjects who appear to be intoxicated or under the influence of a controlled substance
on any day of assessment must be rescheduled and may be discontinued based upon the
discretion of the investigator
4. Subjects on medications that affect the cognition in the last 12 hours prior to the
study visits that assess the cognitive functions
We found this trial at
1
site
Old Westbury, New York 11568
Principal Investigator: Anu Raj, Psy.D
Phone: 516-686-4909
Click here to add this to my saved trials